Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
Sponsor: Raphael Pharma
Summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Key Details
Gender
All
Age Range
25 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-06-03
Completion Date
2024-12-31
Last Updated
2024-11-21
Healthy Volunteers
No
Conditions
Interventions
Cannabigerol (CBG)
The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Locations (1)
Citruslabs
Santa Monica, California, United States